Neal D. Shore, MD, FACS, presented “HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer” for the Grand Rounds in Urology audience in June, 2020.
HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer – Summary:
Neal D. Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center, presents the key aspects of the HERO phase 3 trial. The HERO trial looked at Relugolix, an oral GnRH receptor antagonist, versus Leuprolide Acetate for the treatment of advanced prostate cancer. He begins by going over the study design, patient demographics, and clinical characteristics. He then goes over some of the study’s key and secondary endpoints, all of which were met.
In this interview, Celestia S. Higano, MD, Professor of Medicine at the University of Washington School of Medicine and section editor of the ADT Next Generation Learning Center on Grand Rounds in Urology, asks Dr. Shore follow-up questions about the HERO trial’s findings, and the implications that this exciting new development in prostate cancer treatment could have in the field of urology.
How to cite: Shore, Neal D. “HERO Phase 3 Trial: Relugolix vs. Leuprolide Acetate for Advanced Prostate Cancer” June, 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/tmprss2-ace-2-and-the-potential-role-of-5aris-and-gnrh-analogues-in-inhibiting-covid-19-infection/
ABOUT THE AUTHOR
Neal D. Shore, MD, FACS, is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 350 clinical trials, focusing mainly on genitourinary oncology, and serves on the executive boards of the Society of Urologic Oncology and the Bladder Cancer Advocacy Network. He is Past President of the Large Urology Group Practice Association. He is a founder for both CUSP Clinical Trials Consortium and DASHKO, a national urology practice data registry. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank, and the Editorial Boards of Review in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, and World Journal of Urology. He serves as Editor of Everyday Urology-Oncology. Dr. Shore has written more than 200 peer-reviewed publications and numerous book chapters. He performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, the Journal of Urology, Urology, BJUI, PCPD, and numerous other high-impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
